BioVie Inc. (BIVI)
NASDAQ: BIVI · Real-Time Price · USD
1.580
-0.030 (-1.86%)
At close: Dec 5, 2025, 4:00 PM EST
1.520
-0.060 (-3.80%)
After-hours: Dec 5, 2025, 4:40 PM EST
Company Description
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States.
The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis.
It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
BioVie Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Cuong Viet Do |
Contact Details
Address: 680 W. Nye Lane, Suite 204 Carson City, Nevada 89703 United States | |
| Phone | 775 888 3162 |
| Website | bioviepharma.com |
Stock Details
| Ticker Symbol | BIVI |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001580149 |
| CUSIP Number | 09074F504 |
| ISIN Number | US09074F5044 |
| Employer ID | 46-2510769 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Cuong Viet Do M.B.A. | President, Chief Executive Officer and Director |
| Joanne Wendy Kim CPA | Chief Financial Officer, Treasurer and Corporate Secretary |
| Dr. Joseph M. Palumbo M.D. | Executive Vice President of Research & Development and Chief Medical Officer |
| Clarence N. Ahlem | Senior Vice President of Operations |
| Dr. Penelope Markham Ph.D. | Senior Vice President of Liver Disease Program |
| Denise Smith | Senior Vice President of Manufacturing and Development |
| Dr. Christopher L. Reading Ph.D. | Senior Vice President of Alzheimer's Disease Program |
| David Morse | Senior Vice President and Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 18, 2025 | EFFECT | Notice of Effectiveness |
| Nov 13, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Oct 6, 2025 | POS AM | Post-Effective amendments for registration statement |
| Oct 6, 2025 | POS EX | Filing |
| Oct 6, 2025 | 424B3 | Prospectus |
| Sep 25, 2025 | DEF 14A | Other definitive proxy statements |
| Aug 15, 2025 | 10-K | Annual Report |